| Baseline | Flupirtine 200 mg | Placebo | Control | Paired t-test p, baseline vs. flupirtine | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Strength-duration time constant (ms) | 0.48 | ± | 0.01 | 0.47 | ± | 0.01 | 0.47 | ± | 0.01 | 0.47 | ± | 0.01 | 0.18 |
Rheobase (mA) | 2.87 | ± | 0.14 | 3.04 | ± | 0.18 | 2.67 | ± | 0.15 | 2.82 | ± | 0.14 | 0.20 |
Relative Refractory Period (RRP ms) | 3.40 | ± | 0.10 | 3.23 | ± | 0.09 | 3.45 | ± | 0.12 | 3.54 | ± | 0.13 | < 0.01 |
Refractoriness at 2 ms (%) | 165.00 | ± | 13.96 | 105.83 | ± | 10.12 | 169.77 | ± | 33.36 | 138.68 | ± | 9.49 | 0.01 |
Refractoriness at 2.5 ms (%) | 66.27 | ± | 8.86 | 40.09 | ± | 6.20 | 60.28 | ± | 8.88 | 60.21 | ± | 5.84 | 0.02 |
Superexcitability at 5 ms (%) | −24.57 | ± | 1.49 | −24.73 | ± | 1.55 | −24.11 | ± | 1.99 | −23.28 | ± | 1.54 | 0.89 |
Superexcitability at 7 ms (%) | −27.12 | ± | 1.42 | −25.69 | ± | 1.67 | −27.05 | ± | 1.57 | −26.71 | ± | 1.32 | 0.09 |
Depolarisation TEd (90–100 ms) | 40.04 | ± | 0.78 | 40.37 | ± | 4.25 | 40.23 | ± | 1.11 | 39.74 | ± | 0.96 | 0.69 |
Hyperpolarisation TEh (90–100 ms) | −107.61 | ± | 3.01 | −106.31 | ± | 2.82 | −107.07 | ± | 4.63 | −106.30 | ± | 2.92 | 0.50 |
Skin Temperature (°C) | 31.89 | ± | 0.22 | 32.20 | ± | 0.29 | 31.95 | ± | 0.32 | 31.74 | ± | 0.24 | 0.13 |